- $243.46m
- $258.53m
- $32.63m
- 55
- 26
- 89
- 58
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 123.9 | ||
| Price to Sales | 7.46 | ||
| EV to EBITDA | 20.06 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | 35.98% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.06 | 13.01 | 16.74 | 20.4 | 32.63 | n/a | n/a | 99.65% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others.
Directors
- Kevin Richardson CHM (52)
- Lisa Sundstrom CFO (50)
- Peter Stegagno COO (60)
- Iulian Cioanta CTO (57)
- A. Michael Stolarski DRC (49)
- John Nemelka IND (54)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 6th, 2004
- Public Since
- November 7th, 2008
- No. of Shareholders
- 204
- No. of Employees
- 46
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 8,548,473
- Address
- 11495 Valley View Road, EDEN PRAIRIE, 55344
- Web
- https://sanuwave.com/
- Phone
- +1 7704197525
- Auditors
- Marcum LLP
Upcoming Events for SNWV
Q2 2025 SANUWAVE Health Inc Earnings Release
Similar to SNWV
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Beta Bionics
NASDAQ Global Market
FAQ
What is the SANUWAVE Health share price?
As of Today at 23:04 UTC, shares in SANUWAVE Health are trading at $28.48. This share price information is delayed by 15 minutes.
How has the SANUWAVE Health share price performed this year?
Shares in SANUWAVE Health last closed at $28.48 and the price had moved by +305.7% over the past 365 days. In terms of relative price strength the SANUWAVE Health share price has outperformed the S&P500 Index by +274.47% over the past year.
What are the analyst and broker recommendations for SANUWAVE Health?
The overall consensus recommendation for SANUWAVE Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the SANUWAVE Health dividend yield?
SANUWAVE Health does not currently pay a dividend.
Does SANUWAVE Health pay a dividend?
SANUWAVE Health does not currently pay a dividend.
When does SANUWAVE Health next pay dividends?
SANUWAVE Health does not currently pay a dividend.
How do I buy SANUWAVE Health shares?
To buy shares in SANUWAVE Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of SANUWAVE Health?
As of the previous close price of $28.48, shares in SANUWAVE Health had a market capitalisation of $243.46m.
Where are SANUWAVE Health shares listed?
Here are the trading details for SANUWAVE Health:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: SNWV
What kind of share is SANUWAVE Health?
Based on an overall assessment of its quality, value and momentum SANUWAVE Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a SANUWAVE Health share price forecast for 2025?
The analyst consensus target price for shares in SANUWAVE Health is $0.34. That is 98.81% below the last closing price of $28.48.
Analysts covering SANUWAVE Health currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the SANUWAVE Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SANUWAVE Health. Over the past six months, its share price has outperformed the S&P500 Index by +71.53%.
As of the last closing price of $28.48, shares in SANUWAVE Health were trading +48% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the SANUWAVE Health PE Ratio?
The SANUWAVE Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $28.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of SANUWAVE Health?
SANUWAVE Health's management team is headed by:
- Kevin Richardson - CHM
- Lisa Sundstrom - CFO
- Peter Stegagno - COO
- Iulian Cioanta - CTO
- A. Michael Stolarski - DRC
- John Nemelka - IND